Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlobeStar Therapeutics (GSTC)
OTHER OTC:GSTC
GlobeStar Therapeutics (GSTC) Stock Price & Analysis
12 Followers
GSTC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range― - ―
Previous Close$0.01
Volume1.24M
Average Volume (3M)N/A
Market Cap
$930.34K
Enterprise Value$1.30M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$368.67K
Price to Earnings (P/E)-4.3
Beta-0.19
Next Earnings
Feb 15, 2018EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,162,921,101
10 Day Avg. Volume2,964,771
30 Day Avg. VolumeN/A
Standard Deviation0.75
R-Squared0.01
Alpha0.09
Financial Highlights & Ratios
Price to Book (P/B)-0.61
Price to Sales (P/S)-5.68
Price to Cash Flow (P/CF)-5.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-7.93
Enterprise Value/Gross Profit-30.76
Enterprise Value/Ebitda-0.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ownership Overview
6.92%
Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
93.08% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GSTC FAQ
What was GlobeStar Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is GlobeStar Therapeutics’s market cap?
Currently, no data Available
When is GlobeStar Therapeutics’s upcoming earnings report date?
GlobeStar Therapeutics’s upcoming earnings report date is Feb 15, 2018 which is 2256 days ago.
How were GlobeStar Therapeutics’s earnings last quarter?
Currently, no data Available
Is GlobeStar Therapeutics overvalued?
According to Wall Street analysts GlobeStar Therapeutics’s price is currently Overvalued.
Does GlobeStar Therapeutics pay dividends?
GlobeStar Therapeutics does not currently pay dividends.
What is GlobeStar Therapeutics’s EPS estimate?
GlobeStar Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlobeStar Therapeutics have?
GlobeStar Therapeutics has 1,162,921,100 shares outstanding.
What happened to GlobeStar Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of GlobeStar Therapeutics?
Among the largest hedge funds holding GlobeStar Therapeutics’s share is Fisher Asset Management LLC. It holds GlobeStar Therapeutics’s shares valued at N/A.
---
GlobeStar Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-100.00%
Trailing 12-Months
Company Description
GlobeStar Therapeutics
AngioSoma, Inc. is a wellness company, which engages in the manufacture and marketing of pharmaceuticals and nutraceutical supplements. It operates through the following segments: Nutraceuticals, Cosmeceuticals, and Pharmaceuticals. AngioSoma also develops Liprostin for the treatment of peripheral artery disease. The company was founded by David P. Summers on April 29, 2016 on and is headquartered in Houston, TX.
---
---